52200-18-7 Usage
Description
2-[(DIMETHYLAMINO)METHYLENE]-3-(4-BROMOPHENYL)-3-OXO-PROPANENITRILE, also known as BOC-L-Asparagine-4-Nitrophenyl Ester, is a chemical compound with the molecular formula C13H13BrN2O2. It is a yellow solid that is commonly used in organic chemistry as a reagent for the synthesis of peptides and other organic compounds. It is known for its ability to act as a strong base and can participate in various reactions such as the Wittig reaction and Michael addition. Due to its potential health and environmental risks, it is considered to be hazardous and should be handled with care.
Uses
Used in Organic Chemistry:
2-[(DIMETHYLAMINO)METHYLENE]-3-(4-BROMOPHENYL)-3-OXO-PROPANENITRILE is used as a reagent for the synthesis of peptides and other organic compounds. Its strong base properties allow it to participate in various reactions, such as the Wittig reaction and Michael addition, making it a valuable component in the creation of complex organic molecules.
Check Digit Verification of cas no
The CAS Registry Mumber 52200-18-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,2,2,0 and 0 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 52200-18:
(7*5)+(6*2)+(5*2)+(4*0)+(3*0)+(2*1)+(1*8)=67
67 % 10 = 7
So 52200-18-7 is a valid CAS Registry Number.
InChI:InChI=1/C12H11BrN2O/c1-15(2)8-10(7-14)12(16)9-3-5-11(13)6-4-9/h3-6,8H,1-2H3/b10-8+
52200-18-7Relevant articles and documents
Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds
Niculescu-Duvaz, Dan,Niculescu-Duvaz, Ion,Suijkerbuijk, Bart M.J.M.,Ménard, Delphine,Zambon, Alfonso,Nourry, Arnaud,Davies, Lawrence,Manne, Helen A.,Friedlos, Frank,Ogilvie, Lesley,Hedley, Douglas,Takle, Andrew K.,Wilson, David M.,Pons, Jean-Francois,Coulter, Tom,Kirk, Ruth,Cantarino, Neus,Whittaker, Steven,Marais, Richard,Springer, Caroline J.
experimental part, p. 6934 - 6952 (2010/11/03)
V-RAF murine sarcoma viral oncogene homolog B1 (BRAF) is a serine/threonine-specific protein kinase that is mutated with high frequency in cutaneous melanoma, and many other cancers. Inhibition of mutant BRAF is an attractive therapeutic approach for the treatment of melanoma. A triarylimidazole BRAF inhibitor bearing a phenylpyrazole group (dimethyl-[2-(4-{5-[4-(1H-pyrazol-3-yl)-phenyl]-4-pyridin-4-yl-1H-imidazol-2-yl} -phenoxy)-ethyl]-amine, 1a) was identified as an active BRAF inhibitor. Based on this starting point, we synthesized a series of analogues leading to the discovery of 6-{2-[4-(4-methyl-piperazin-1-yl)-phenyl]-5-pyridin-4-yl-3H- imidazol-4-yl}-2,4-dihydro-indeno[1,2-c]pyrazole (1j), with nanomolar activity in three assays: inhibition of purified mutant BRAF activity in vitro; inhibition of oncogenic BRAF-driven extracellular regulated kinase (ERK) activation in BRAF mutant melanoma cell lines; and inhibition of proliferation in these cells.